Related Experiment Video

Updated: Jun 16, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Trends in therapeutic monoclonal antibodies of cancer

Wenfang Shi1, Cunye Qu, Qijun Qian

  • 1The Second Military Medical University, Laboratory of Viral and Gene Therapy, Eastern Hepatobilliary Surgical Hospital, 225 Changhai Road, Shanghai 200438, P.R. China.

Expert Opinion on Therapeutic Patents
|February 11, 2010
PubMed

Insights

Therapeutic monoclonal antibodies show great success in treating diseases, especially cancers. This review explores their development, patent landscape, and future potential in human oncology applications.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Therapeutic monoclonal antibodies have seen increasing clinical success and FDA approvals since 1997.
  • Industry investment in antibody development highlights significant market potential and therapeutic benefits.
  • Monoclonal antibodies are established immunotherapies effective against refractory diseases, particularly cancers.

Purpose of the Study:

  • To review potential therapeutic monoclonal antibodies in oncology.
  • To analyze related antibody patents.
  • To discuss trends in antibody development and human therapeutic applications.

Main Methods:

  • Literature review of FDA-approved antibody products and expanded indications.
  • Analysis of patent applications associated with therapeutic monoclonal antibodies.
  • Exploration of emerging target molecules and future antibody development.

Main Results:

  • Monoclonal antibodies demonstrate profound effects in treating various cancers and other formidable diseases.
  • Numerous patent applications are linked to both the development and approval of therapeutic monoclonal antibodies.
  • Advancements in understanding cancer-immune interactions are leading to new therapeutic antibody discoveries.

Conclusions:

  • Therapeutic monoclonal antibodies are a cornerstone of modern cancer immunotherapy.
  • The field is rapidly evolving, with ongoing discovery of novel targets and improved antibody therapeutics.
  • Patent activity underscores the commercial and scientific importance of antibody development in oncology.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...